Maria Vidal1 article listing Maria Vidal in Nature Communications, indexed by Paperzzz from Crossref and OSF.Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO) Nature Communications